Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Bought Deal

<< Previous

Bullboard Posts

Next >>

Comment by RalphRalphon Feb 17, 2021 5:45pm

170 Views

Post# 32588370

RE:RE:RE:RE:Bought Deal

The offering also includes warrants - very disappointing. The company still having to include warrants in financing is not good to see. Was hoping to see a deal without warrants - this is a failing on management's part IMO. Biotech companies with appealing assets and high offering demand don't typically include warrants when they raise.

JimmyJ wrote: Marky, in the long run this is great news. Short term, the sp will likely drop below $6 tomorrow, possibly even mid to low 5's. If it does, look at it as an opportunity to accumulate low because it won't last long.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec